Blog

The importance of continuity of operations plans for gene therapy manufacturers

By: James Zoshak The COVID-19 pandemic has added increased risk and uncertainty to gene therapy…

Certara2021 年 2 月 22 日

Brochure

Gene Therapy Platform using Certara’s Virtual Twin® Technology

Certara2021 年 2 月 22 日

Blog

Why consistency in patient safety narratives is crucial

“You would not be able to tell 40 different writers were authoring these. It looked…

Certara2021 年 2 月 9 日

Publication

BPS Article: 模型引导的药物再利用：新型病原体准备、反应和回顾的定量药理学方法

Abstract During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential…

Certara2021 年 2 月 9 日

On-Demand Webinar

RAPS 赞助的网络研讨会：效率与技术为产品说明撰写的新时代铺平道路

医学叙述是医学写作的核心组成部分。Sponsors sometimes need to prepare large…

Certara2021 年 2 月 8 日

Blog

成功开发寡核苷酸疗法的 8 条小贴士

By Eva Gil Berglund and Nathalie H Gosselin Oligonucleotide therapeutics are a validated class of…

Certara2021 年 2 月 1 日

On-Demand Webinar

How drug developers can avoid these common mistakes to secure a deal

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

Certara2021 年 1 月 21 日

On-Demand Webinar

Making your biotech program investor-ready

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

Certara2021 年 1 月 21 日

On-Demand Webinar

新兴生物技术公司资产评估简介

Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…

Certara2021 年 1 月 21 日

White Paper

“要从哪里开始？”：选择首次人体临床试验的起始剂量

This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…

Certara2020 年 12 月 22 日

pre-update

The importance of continuity of operations plans for gene therapy manufacturers

Gene Therapy Platform using Certara’s Virtual Twin® Technology

Why consistency in patient safety narratives is crucial

BPS Article: 模型引导的药物再利用：新型病原体准备、反应和回顾的定量药理学方法

RAPS 赞助的网络研讨会：效率与技术为产品说明撰写的新时代铺平道路

成功开发寡核苷酸疗法的 8 条小贴士

How drug developers can avoid these common mistakes to secure a deal

Making your biotech program investor-ready

新兴生物技术公司资产评估简介

“要从哪里开始？”：选择首次人体临床试验的起始剂量

订阅时事通讯

快捷链接

解决方案

联系我们